Harbour BioMed OK'd to Start China Trial of CTLA-4 Antibody for NSCLC

Harbour BioMed was approved to start a China trial of its next-gen anti-CTLA-4 antibody in patients with advanced NSCLC and other solid tumors. The CTLA-4 antibody will be administered in combination with a PD-1 antibody or the PD-1 together with chemotherapy. HBM says the candidate is a fully human anti-CTLA-4 monoclonal heavy chain only antibody generated by its proprietary Harbour Mice ® platform. HBM is headquartered in Cambridge , MA , with drug discovery operations in Rotterdam and an R&D facility in Suzhou . More details.... Stock Symbol: (HKEX: 02142) Share this with colleagues: // //